DGAP-News: Photo Release — Apricus Biosciences Announces FDA Clearance for Its First Anti-Fungal OTC Drug (Tolnaftate-D(TM)) Containing NexACT(R) Technology
Apricus Biosciences, Inc.
18.08.2011 15:00
—————————————————————————
DDAIP Now Listed on U.S. Monograph for OTC Products
SAN DIEGO, 2011-08-18 15:00 CEST (GLOBE NEWSWIRE) —
Apricus Biosciences, Inc. (–Apricus Bio– or the –Company–) (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that its wholly owned subsidiary,
NexMed USA, has received clearance from the U.S. Food and Drug Administration
(–FDA–) to market its first anti-fung
